Aardvark Therapeutics (NASDAQ:AARD) Coverage Initiated at Bank of America

Investment analysts at Bank of America began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a report released on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $22.00 price target on the stock. Bank of America‘s price objective indicates a potential upside of 111.13% from the stock’s current price.

Several other equities research analysts have also commented on the company. Cantor Fitzgerald began coverage on Aardvark Therapeutics in a research report on Monday. They issued an “overweight” rating and a $50.00 price objective on the stock. Royal Bank of Canada assumed coverage on shares of Aardvark Therapeutics in a report on Monday. They set an “outperform” rating and a $21.00 price target on the stock.

Aardvark Therapeutics Price Performance

Shares of AARD opened at $10.42 on Monday. Aardvark Therapeutics has a 52 week low of $9.21 and a 52 week high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In related news, CEO Tien-Li Lee bought 16,542 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Nelson Sun purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the purchase, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.